



#### **CSAM Health Group AS**

Quarterly Report Q1-23 12 May 2023 Emergency response and healthcare *niche software* The leading provider in the Nordics, growing across Europe and beyond

## CSAM's software facilitates life-changing milestones

## Vital solutions for 500 healthcare and emergency response organisations across 27 countries






### **Developing diversified and growing business areas**








Note: YTD 2023

















## **Reported sales outside the Nordics** increased to 14% vs 12% in Q1-22




### **Growing the EBITDA margin through BIB**




### **Current BIB integration project portfolio**



#### BIB history and the plan to reach 30% EBITDA margin



#### Team Task: From 5% EBITDA margin in Q1-23 to ~30% in Q3-23




## **Business Area breakdown**

Key figures per Business Area	Sales <sup>(1)</sup>	EBITDA	Capex	Organic growth
Connected Healthcare	12.9	-1 %	2 %	18 %
Health Analytics	6.7	8 %	0 %	1 %
LIMS	12.6	-30 %	16 %	-9 %
Medical Imaging	7.4	14 %	23 %	11 %
Medication Management	3.4	14 %	0 %	-19 %
Public Safety	45.5	13 %	9 %	15 %
Women & Children's Health	11.6	13 %	3 %	-7 %

#### Comments


- Expect quarterly lumpiness in BA's as booked income is based on delivery milestones. Applies this quarter to:
  - LIMS
  - Medication Management
  - Women & Children's Health
- Connected Healthcare: Consultants on a temporary basis related to growth
- Health Analytics: Still in BIB integration mode

### From Nordic to Pan-European - and beyond




# FINANCIALS

#### CSAM's recurring software revenues are steadily increasing




Note: Quarterly revenue development recurring revenue LFQ (NOKm)

## Favourable revenue mix




#### 


## **Cost improvements to continue throughout 2023**



#### **EBITDA** margin will gradually move towards 30%



## Net working capital development improving




#### Comments

• CSAM has a communicated NWC target of -10% or better

• When acquiring companies, it takes some time before CSAMs NWC policies are applied in the acquired companies, hence NWC development will vary.


### CSAM investors per May 2023




## **Concluding remarks**

- 1. Organic growth
- 2. Profitability
- 3. M&A high activity, but will remain disciplined
- 4. Decentralised and empowered organisation
- 5. Gradual improvements next quarters

### Where we came from and where we are heading



### **Our ambitions remain**



**Current long term recurring revenues** 

Focus on specialised software for healthcare

Large underlying market with structural growth

2021

## Subscribe to our newsletter

#### Subscribe to our news

#### First Name

#### Last Name


#### Email address

#### **News Types**

- Financial News
- General News

I have read and agree to the terms & conditions





## Thank you!